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Summary Bryostatin I is a novel macrocyclic lactone activator of protein kinase C (PKC) which has clinical
potential as an anti-cancer agent. The mechanism of action of this agent is unknown, but protein kinase C has
been implicated. In order to investigate this possibility, we have developed P388 sublines resistant to bryostatin
1. by continuous challenge of the parent cell line with increasing incremental concentrations of the drug over 4
months. Cell lines were established at monthly intervals yielding four sublines: P388 BR A. which were
removed at I month; P388'BR/B, obtained after 2 months; P388,BR C. obtained after 3 months; and
P388 BR/D. which were established after 4 months. All four P388 BR sublines show an equal degree of
resistance to the growth inhibitory effects of bryostatin 1. with a relative resistance ratio (RR) IC5, of
approximately 4,000. The ability of the cytosol ofcells to phosphorylate PKC-specific substrate is decreased by
41% for BR A. 57% for BR/B 80% for BR C and 94% for BR 'D compared with the parental cell line. even
when grown in the absence of bryostatin 1 for up to 4 weeks. Similar decreases are seen for cytosolic phorbol
ester binding and whole-cell PKC isoenzyme expression. All four P388 BR sublines show high and equal levels
of cross-resistance to the PKC activatory phorbol ester, phorbol 12-myristate 13-acetate (PMA). There is no
loss of resistance to either bryostatin I or PMA up to 3 months after termination of exposure of the sublines
to bryostatin 1. There was no significant degree of cross-resistance to daunorubicin in the bryosatin 1-resistant
cell lines, P388 BR A, B. C or D, when compared with the parent cell line. P388.
Bryostatin 1 is the prototype of a family of naturally occurr-
ing activators of protein kinase C (PKC) (Berkow & Kraft,
1985; Smith et al., 1985; Kraft et al., 1986; Fields et al.,
1988). It is a macrocyclic lactone (see Figure 1) isolated from
the marine invertebrate Bugula neritina, a member of the
phylum Ectoprocta (Pettit et al., 1982). Bryostatin 1 exerts a
wide range of biological effects, including antineoplastic
activity. induction of differentiation, haemopoietic stimula-
tion, platelet aggregation and immunoenhancing activity.
Significant antineoplastic activity has been demonstrated
against leukaemias, lymphomas, ovarian sarcoma, reticulum
cell sarcoma and melanoma in a variety of murine and
human cell lines and also in vivo against murine tumours-
(NCI Antitumour Screening Program; Pettit et al., 1982;
Dale & Gescher, 1989; Hornung et al., 1992). Bryostatin I
therefore has potential as an anti-cancer agent and it is
currently undergoing phase I and phase II clinical trials in
patients with malignant disease at the Christie Hospital, as
part of the Cancer Research Campaign clinical trials
initiative.
Bryostatin I shares many of its biological effects with
phorbol esters, which are potent activators of PKC (Cas-
tagna et al.. 1982). In several biological systems, however,
bryostatin 1 behaves differently from phorbol esters. Unlike
phorbol esters, bryostatin 1 does not induce differentiation in
human bronchial epithelium (Jetten et al., 1989) or primary
mouse epidermal cells (Sako et al., 1987). Furthermore,
bryosatin I and phorbol esters show differential effects on the
hydrolysis of phosphatidylethanolamine (Kiss et al., 1991).
Furthermore. bryostatin 1 is inactive as a complete tumour
promoter or carcinogen and acts to inhibit the tumour-
promoting properties of phorbol esters (Hennings et al.,
1987). Some of these differences may be attributed to the
diversity of responses to PKC activation mediated by the
multiple isoforms that constitute the PKC family (a, , y, c,
a, s.,., etc.) and their tissue-selective distribution (Nishizuka,
1988; Parker et al., 1989; Gescher, 1992). Differences in the
nature of the binding to the PKC receptor may provide an
alternative mechanism for generating heterogeneity (Konig et
al., 1985; Nakadate & Blumberg, 1987; Nelsestuen & Bazzi,
1991; Blumberg & Pettit, 1992).
The substantial involvement of protein kinase C in cellular
signal transduction gives it a central position in the regula-
tion of growth and differentiation. It is, therefore, of great
importance to identify and understand the mechanisms that
account for the multiplicity of response within the protein
kinase C pathway (Azzo et al., 1992). In order to investigate
the role of PKC in the anti-tumour effect of bryostatin 1, we
have developed murine leukaemia sublines exhibiting resis-
tance to the growth-inhibitory effects of the drug. These have
been compared with the parental line in terms of their PKC
activities and isoenzyme expression in order to determine
whether alterations in this signalling is associated with
decreased response to this agent.
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Materias and methods
Drugs and chemicals
Phorbol 12-myristate 13-acetate (PMA) used in the growth
inhibition assays and dimethylsulphoxide (DMSO) were
obtained from Sigma, UK, 3H-labelled phorbol dibutyrate
([3HJPDBu) from New England Nuclear UK, and Ethanol
AR was supplied by BDH. PMA used in the PKC assay,
phosphatidylserine, Triton X-100 mixed micelles, PKC sub-
strate [Ac-MBP (4-14)], PKC inhibitor [PKC (19-36)], cal-
cium chloride, Tris, leupeptin, aprotinin, P-mercaptoethanol
and sodium chloride were obtained from Gibco BRL, UK.
Specific anti-peptide antisera for PKC isoforms (x, P1, pII, t,
c) were a kind gift from W.F. Heath, Lilly Research
Laboratories. RPMI medium and horse serum were also
obtained from Gibco BRL.
Cell culture
P388 is an immortal murine acute leukaemia cell line. P388
PR8/22 is a P388 cell line with acquired resistance to
daunorubicin (DnR), which was previously developed from
the parental cell line, P388, by incremental challenge with
DnR in vitro (McGown et al., 1983). Both cell lines were
grown as a suspension culture in RPMI medium supple-
mented with 10% horse serum. P388 PR8/22 was routinely
maintained in the presence of DnR (0.1 g ml-') except dur-
ing experimental procedures. All cell lines were mycoplasma
free and replaced from frozen stock at 3 month intervals.
All cell lines were grown in the absence of bryostatin 1 for
4 weeks before experimentation.
Cell size was measured using a Coulter Channelizer
256.
Establishment P388 sublines resistant to bryostatin 1-induced
growth inhibition
We established P388 sublines resistant to bryostatin 1-
induced growth inhibition by continuous exposure to increas-
ing concentrations of the drug in vitro for over 4 months.
Briefly, exponentially growing P388 cells were collected and
adjusted to I03cells ml-'. Ten millilitres of this cell suspen-
sion was plated in 50 cm2 flasks and incubated for 7 days at
37C in a humidified atmosphere containing 5% carbon diox-
ide. Bryostatin I was dissolved in 100% ethanol and added
at a final concentration of 0.5% ethanol to the cell suspen-
sion each week after the cells had been readjusted to
IO3cellsml-' in fresh medium. The cell suspension was
initially maintained in bryostatin 1 at a concentration of
0.5 nM and by gradual weekly increments was increased over
4 months to 1,000 nM. Cells were removed from bryostatin I
challenge at monthly intervals (P388/BR/A, removed at 1
month and up to 50 nM bryostatin 1 challenge; P388/BR/B, 2
months and 100 nM; P388/BR/C, 3 months and 500 nM; and
P388/BR/D, 4 months and 1,000 nM), adjusted to 106cells
ml-' and frozen in triplicate at -270'C. On removal from
the freezer, P388/BR/B, C and D were cultured in bryostatin
1-free medium for at least 4 weeks before each experi-
ment.
Growth inhibition studies
Each drug (bryostatin 1, PMA or DnR) was tested for its
ability to inhibit the growth of each cell line (P388, P388
PR8/22 or P388/BR/A, B, C or D) when exposed continu-
ously to the cells for 5 days. Bryostatin I was dissolved in
ethanol, PMA in DMSO and DnR in water. Exponentially
growing cells were adjusted to I0 cells ml-' and plated in
2 ml wells. Various concentrations of drug were added to
appropriate wells with the final concentration of diluent
0.5% (v/v). Cells were incubated for 5 days. Cell number was
determined in each well using a Coulter counter and a
growth curve was constructed. Each experiment was per-
formed in quadruplicate and carried out three times. The IC5o
was defined as the drug concentration necessary to achieve a
50% inhibition of cell growth when compared with the con-
trol. Relative resistance was defined as:
IC50 for resistant subline
Relative resistance = ICSo for parental cell line
Whole-cellprotein kinase C assay
Assay of PKC was based on measurement of the phos-
phorylation of an acetylated synthetic peptide based on
myelin basic protein, Ac-MBP (4-14; Yasuda et al., 1990).
PKC specificity was confirmed by using the PKC pseudo-
substrate inhibitor peptide PKC (19-36), which inlhibits
PKC-catalysed substrate phosphorylation potently (Yasuda
et al., 1990).
Cells (approximately 1 x 10' per assay) were rapidly
sedimented, washed with ice-cold phosphate-buffered saline
and resuspended in ice-cold extraction buffer (20mM Tris,
pH 7.5, 0.5 mM EDTA, 0.5 mM EGTA, 0.5% Triton X-100
and 25pg ml-' each aprotinin and leupeptin) and sonicated.
PKC was partially purified by binding to DEAE (diethylam-
moethyl) cellulose, which was equilibrated with ice-cold wash
buffer (20 mM Tris, pH 7.5, 0.5 mM EDTA and 0.5 mM
EGTA). PKC was collected as a single fraction with ice-cold
elution buffer (20 mM Tris, pH 7.5, 0.5 mM EDTA, 0.5 mM
EGTA, 10 mM P-mercaptoethanol and 0.2 M sodium chlor-
ide). Enzyme activity was assayed in triplicate after a 5 mi
incubation at 30eC of a reaction mixture containing 20 mM
Tris, pH 7.5, 20 mM magnesium chloride, 1 mM calcium
chloride, 20gM ATP, 0.2iLCi of [-_32PJATP, 50ltM Ac-MBP
(4-14), 0.25 mM EDTA, 0.25 mM EGTA, 5 mM P-mercapto-
ethanol and 0.1 M sodium chloride with either IO M PMA,
0.28 mg ml-' phosphatidylserine and Triton X-100 mixed
micelles or 20tiM PKC inhibitor, PKC (19-36). Reactions
were terminated by spotting aliquots of the reaction mnixture
onto individual phosphocellulose discs, which were washed
with 1% (v/v) phosphoric acid and water to remove non-
incorporated e-ATP. Each phosphocellulose disc was placed
in a scintillation vial with scintillation fluid (10 ml) for
measurement of radioactivity in a Beckman (USA) LS 1801
scintillation counter. Conditions were adjusted to ensure that
the reaction was linear with respect to time ofincubation and
concentration of cells.
Phorbol ester binding assay
Formation of mixed micelles from a semipurified extract of
the cytosolic fraction and measurement of phorbol ester
receptor binding were performed as described by Hannun
and Bell (1987) using [HJPDBu as ligand. Non-specific
binding was <10% of total binding.
PKC isoenzyme expression
The expression of PKC isoenzymes m, R. Y and a was
studied. Cells in exponential growth were pelleted by cent-
rifugation and washed twice with ice-cold PBS. Pellets were
lysed in 3001.l of SDS reducing buffer [0.0625 M Tris-HCI,
glycerol 10% (v/v), SDS 2% (w/v), 2-P mercaptoethanol 5%
(v/v) 1.25 x 10-3% (w/v) bromophenol blue]. The lysate was
heated to 95-C for 10 min. An aliquot of lysate equivalent to
35jg of protein was subjected to 10% SDS-PAGE and
electrotransferred to nitrocellulose paper with a current of
60 mA for 1 h. The nitrocellulose membrane was stored over-
night at 4'C in blocking buffer (5 g of casein milk powder in
lOOml or TBS/Tween [1.211glg' Tris, 8.18gl-' sodium
chloride, 0.001% (v/v) Tween 20, pH 7.4]. The nitrocellulose
membrane was exposed for 2 h to monoclonal antibodies
against PKC-a, -P, -0,, -a and -y. The nitrocellulose mem-
brane was washed five times with blocking buffer and then
stained for I h with anti-rabbit Ig peroxidase conjugate
diluted 1:1,000 in blocking buffer. The nitrocellulose was
then further washed five times with TBS/Tween. The
immunoreactive bands were then visualised using the ECLRESISTANCE TO BRYOSTATIN 1 575
Western blotting detection system (Amersham, UK) accord-
ing to the manufacturer's instructions.
Results
Cell growth
P388 cells were exposed to bryostatin I for up to 4 months.
Bryostatin I was removed from the medium after 1, 2, 3 or 4
months and the cell lines obtained were designated P388/BR/
A. B, C and D respectively. After removal of the drug the
cells grew at the same rate as the parental cell line. Signifi-
cant differences were not observed in either cell size or pro-
tein content between the parent cell line and the sublines
which had been exposed to bryostatin 1. The general charac-
teristics of the parent line (P388) and cell lines P388/BR,A,
P388/BR/B, P388 BR/C and P388/BR/D are summarised in
Table I.
Grow th inhibition
Growth-inhibitory effects were assessed using a 5 day con-
tinuous exposure assay. The growth of P388/BR/A, B, C,
and D cells was not inhibited when they were cultured with
100 nM bryostatin 1, however growth inhibition was seen at
500 nM. At I JiM proliferation of all lines was arrested by
52.6% in the case of P388/BR/A cells, 65.1% for P388/BRz B,
59.9% for P388 BR/C cells and 48.1% for P388/BR1D (see
Figure 2). All sublines showed a similar and very high
relative resistance (RR) to bryostatin 1 (approximately 4,000-
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fold). This high level of resistance developed after 1 month of
incubation with bryostatin 1 at doses of up to 50 nM. Further
incubations for 3 months at doses of up to 1 JiM did not
increase the degree of resistance. Similarly, all four P388/BR
sublines also showed a high and equal level of cross-resis-
tance to phorbol 12-myristate 13-acetate (PMA), with an RR
of approximately 4,000 also (Figure 3). Resistance to either
bryostatin I or PMA was not lost up to 3 months after
removal of the cells from the bryostatin 1 challenge. The IC50
of DnR for P388 (6 nM) was very similar to that seen in the
bryostatin 1-resistant cell lines P388BR/A (9.5 nM), P388/BR/
B (10.2 nM), P388/BR/C (9.8 nM) and P388/BR/D (10.5 nM)
(Figure 4). The IC50 of bryostatin 1 for P388 (0.25 nM) was
almost the same as that in the daunorubicin-resistant cell
line, P388 PR8/22 (0.30 nM) (Figure 5).
Whole-cell PKC activity
Whole-cell PKC activity was measured in the parent cell line.
DnR-resistant subline and bryostatin 1-resistant sublines
(Figure 6). Whole-cell PKC activity in response to PMA was
reduced to 59 ± 5% for P388 BRA, 43 ± 3% for BR/B,
20± 6% for BR/C and 6± 2% for BR/D compared with
P388 cells (= 100%). Enzyme activity was not significantly
altered in the daunorubicin-resistant cell line. P388 PR8'22
(110% ± 10%).
Phorbol receptor assay
Cytosolic phorbol ester receptors were reduced in the bryo-
statin 1-resistant sublines to similar degrees as whole-cell
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Fiue 2 Growth inhibition by bryostatin I of parent cell line A
P388 (0) and bryostatin 1-resistant sublines P388/BR/A (*) and
P388 BR/D (A). The error bars show the s.d. from triplicate
measurements.
Fue 3 Growth inhibition by PMA of parent cell line P388
(0) and bryostatin 1-resistant sublines P388,BR,A (*) and P388
BR D (A). The error bars show the s.d. from triplicate
measurements.
Table I Morphological characteristics of parent cell line (P388) and bryostatin I-resistant sublines (P388 BR A, B. C
and D)
P388 BR A BRB BR C BR D
Doubling time (h) 14.6 (± 1.2) 14.8 (± 1.3) 15.1 (± 1.0) 14.9 (± 0.8) 15.2 (± 1.4)
Diameter (gim) 10.09 (± 0.07) 10.27 (± 0.11) 10.32 (± 0.06) 10.38 (± 0.00) 10.37 (± 0.00)
Cell volume (pl) 537.7 (± 10.4) 568.8 (± 17.7) 576.4 (± 9.41) 586.5 (± 0.0) 584.4 (± 0.0)
P388, parent murine leukaemia cell line; BR A, BR/B, BR C and BR/D, bryostatin 1-resistant P388 sublines. Errors are
standard errors of the mean.
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PKC activity: P388BR A (13.90o + 1.470o of P388 control).
P388BR B (34.5 + 1.550o). P388 BR C (15.2 + 1.60o) and
P388 BR D )10.> |2.80o) compared to P388 controls
1000o) (Fizure . C'-tosolic phorbol ester receptor levels
are essentialiv unchangzed in the daunorubicin-resistant sub-
line. P388 PPR8 22 97.8 5.3o00).
PKC isoen.:Yme conftenft
Only PKC-x was expressed in these cells (FFizure 8). An
anal-sis of the expression of the x isoform showed that
expression of this protein is reduced upon exposure to br-o-
statin 1. The expression of the x isoform w-as in the order
0~
5I.
h-
60
c
5;
P388 O000o) >BR A (500o) > BR B > BR C>> BR D.
Indeed. no PKC-x u-as detected in the BR D line bv this
method. These results mirror closel1 the chanzes seen in
whole-cell PKC phosphorylating activitv and cvtosolic PKC
receptors. PKC-c levels in P388 PR8 22 wvere similar to those
found in P388 w-ild-type cells.
Discussion
In common with phorbol esters. br-ostatin 1 is a very potent
actixator of PKC. Br-ostatin 1 induces only a subset of the
characteristic biological responses seen for phorbol esters.
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Figure 4 Growth inhibition bN daunorubicin of parent cell line
P388 (Oi and brvostatin 1-resistant subline P388 BR D (A). The
error bars showv the s.d. from tnrplicate measurements.
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Figure 6 Ahole-cell protein kinase C activity in parent cell line
1P388). daunorubin-resistant subline (P388PR8 22) and bvro-
statin I-resistant sublines (P388 BR A. B. C and D). The error
bars show the s.d. from tnrplicate measurements.
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Figure 5 Growth inhibition bx brxostatin I of parent cell line
P388 (0) and daunorubicin-resistant cell line P388PR8 22 (0).
The error bars shoA the s.d from tn'plicate measurements.
P388 PR8 22 BR A
Figure 7 Cytosolic PKC receptor levels in parent cell line
(P388). daunorubicin-resistant sublines (P338 P338 22 and brvo-
statin 1-resistant sublines (P388 BR A. B. C and D). The error
bars shov the s.d. from tnrplicate measurements.
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PKC-c isoenzyme
STD P388 PR8/22 BR/A BR/B BR/C BR/D
Figwe 8 PKC-ax isoenzyme expression in parent cell line P388.
daunoruibicin-resistant subline (P338 PR8.'22) and bryostatin I-
resistant sublines (P388 BR A. B. C and D).
For those responses which bryostatin 1 fails to induce it
often blocks the same responses to the phorbol ester if the
two compounds are present together (Sako et al.. 1987;
Jetten et al.. 1989). The mechanisms which give rise to this
diversity of response following PKC activation are currently
unclear, but two possibilities which may be involved are (1)
differential stimulation of PKC isoenzymes by bryostatin 1
and PMA and (2) differential binding of the two agents to
PKC.
The murine leukaemiua cell line. P388. is very sensitive to
the growth-inhibitory effects of bryostatin 1 (IC,, = 0.25 nmm)
if exposed for 5 days to the dr-ug. We have established P388
sublines with high levels of resistance to bryostatin 1 by
continuous and increasing incremental challenge with this
drug over 4 months. Each subline was found to possess
relative resistance of approximately 4,000 against bryostatin
1. A sirmilar high level of cross-resistance has also been found
to the phorbol ester. PMA. The reduced activation of PKC
by PMA observed in these sublines - 41% and 94% reduc-
tion for P388 BR A and P388/BR,D respectively compared
with parental cells - shows that the continuation of drug
exposure continued to cause an alteration in PKC content of
the sublines. Similar changes were observed for cytoplasmic
phorbol ester receptor levels. It is not clear whether it is time
of exposure or increase in drug concentration which caused
decreased PKC activity. What is clearly evident is that down-
regulation of PKC as assayed by the methods described is
not linearly related to the decrease in sensitivity to bryostatin
1. However. it is possible that loss of a specific PKC isoen-
zymeas reponsble for conferring bryostatin 1 resistance.
It must be noted that the PKC levels in this study are not
necessarily indicative of the activity of each PKC isoform.
Activity was measured using a specific peptide inhibitor
based on the pseudosubstrate region common to the a. P and
y isoenzymes of PKC. The pseudosubstrate regions for the 6.
C. ~isoenzymes diverge (Parker et al., 1989) and therefore
the inhibitor is probably not recognised by these enzymes.
Similarly. the affinity of the substrate is isoform dependent
(Yasuda et al.. 1990). Therefore, although PKC activitv was
reduced in these cells, it is not possible from the data to draw
conclusions as to specific PKC isoforms. An analysis of these
isoenzymes was necessary to address this issue. The expres-
sion of five individual PKC isoenzymes (cx. P. P. y and e)
was examined. Only cx was detectable in the parental cell line.
P388 (Figure 8). The enzyme showed a gradual decrease in
expression with increasing duration and concentration of
bryostatin 1 exposure reflecting the reductions observed in
whole-cell PKC activity and cytoplasmic phorbol ester recep-
tor levels. No increased expression in P, . y or e was seen
in the resistant cell lines. This result suggests that bryostatin
1 resistance is not associated with selective PKC down-
regulation. although we cannot exclude the possibility that
other PKC isoenzymes are involved. Nevertheless, the result
is strongly suggestive that down-regulation of a cellular sig-
nal transduction pathway other than those involving PKC-a.
-P, -y or -c is important in mediating bryostatin 1 resistance
and that down-regulation of PKC is either just part of the
resistance mechanism or perhaps only an associated finding.
It is not known whether the decreased PKC activity arose
from increased protein turnover or decreased protein produc-
tion.
It is of interest that the P388 BR D subline. with 94% loss
of whole-cell PKC activity, continued to grow at the same
rate in serum supplemented with medium as the parent cell
line. It seems. therefore, that only 6% of the PKC activity as
measured by these techniques need be associated with normal
rates of cell proliferation.
An increased activity of PKC has been reported in certain
multidrug-resistant (MDR) cell lines (Palayoor et al.. 1987).
We observed a small increase in whole-cell PKC activity
when the daunorubicin-resistant cell line. P388 PR8 22, was
compared with the parent cell line. P388. However this in-
crease was not significant.
We could not demonstrate any significant degree of cross-
resistance towards daunorubicin in the brvostatin 1-resistant
cell lines. Equally. bryostatin 1 demonstrates similar growth-
inhibitorv effects on both P388 and the daunorubicin-resis-
tant subline. We conclude that brvostatin 1 is not one of the
'mdr' class of agents. This is in agreement with Hait and De
Rosa (1991). who have shown that a subclone of HL-60
human promyelocytic leukaemia with acquired resistance to
phorbol esters showed no change in sensitivity to doxo-
rubicin.
In conclusion, this work has shown that the relationship
between levels of PKC activity and sensitivity towards bryo-
statin 1 or phorbol esters is a complex one. However, con-
tinuous exposure of cells to bryostatin 1 results in the rapid
development of a stable cell line with decreased total PKC
activity. The importance of this residual PKC activity to cell
proliferation has yet to be determined.
This work was supported by the Cancer Research Campaign. The
cell culture skills of Tim Ward and Sally Haran are ack-
nowledged.
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